Drug Trial Radar · NCT02395172
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
Last checked: Nov 20, 2026Latest source record: Aug 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
792
Actual
Start
Mar 24, 2015
Primary completion
Nov 22, 2017
Study completion Dec 3, 2019
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Mar 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study was to demonstrate superiority with regard to overall survival of avelumab versus docetaxel in participants with programmed death ligand 1 (PD-L1) positive, non-small cell lung cancer (NSCLC) after failure of a platinum-based doublet.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
AvelumabDrug
Participants received 10 milligrams per kilogram (mg/kg) of avelumab as a 1-hour intravenous infusion once every 2 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
DocetaxelDrug
Participants received 75 mg per square meter (m\^2) (per label) of docetaxel by intravenous infusion once every 3 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) Time in Programmed Death Ligand 1 (PD-L1) + Full Analysis Set Population (FAS)Time frame: Time from date of randomization up to 1420 days
Locations
260 sites in 29 countries. Site status is shown where the registry gives one.
University of Alabama
Tuscaloosa, Alabama
Mayo Clinic
Scottsdale , Phoenix, Arizona
Pacific Cancer Medical Center, Inc.
Anaheim, California
Healing Hands Oncology and Medical Care
Lawndale, California
Sutter Gould Medical Foundation
Modesto, California
Sharp Memorial Hospital
San Diego, California
Lynn Cancer Institute Center
Boca Raton, Florida
University Cancer Institute
Boynton Beach, Florida
Holy Cross Hospital Inc.
Fort Lauderdale, Florida
Florida Cancer Specialists-Broadway
Fort Myers, Florida
Florida Cancer Specialists
St. Petersburg, Florida
Florida Cancer Specialists
West Palm Beach, Florida
Northeast Georgia Cancer Care, LLC
Athens, Georgia
Metairie Oncologist, LLC
Metairie, Louisiana
Henry Ford Health System
Detroit, Michigan
Hematology Oncology Associates of Rockland
Nyack, New York
Novant Health Oncology Specialists
Winston-Salem, North Carolina
Oncology Hematology Care
Cincinnati, Ohio
Signal Point Clinical Research Center
Middletown, Ohio
Mercy Clinic Oklahoma Communities, Inc.
Oklahoma City, Oklahoma
Abington Memorial Hospital
Abington, Pennsylvania
Penn State Univ. Milton S. Hershey Medical Center
Hershey, Pennsylvania
Center for Biomedical Research, LLC
Knoxville, Tennessee
SCRI - Tennessee Oncology
Nashville, Tennessee
The Center for Cancer and Blood Disorders
Fort Worth, Texas
University of Texas Health Science Center at Tyler
Tyler, Texas
MultiCare Health System
Tacoma, Washington
Hospital Italiano Regional del Sur
Bahía Blanca, Argentina
Clínica Universitaria Privada Reina Fabiola
Barrio General Paz, Argentina
Centro de Oncologia e Investigacion Buenos Aires
Berazategui, Argentina
Instituto Medico Especializado Alexander Fleming
Ciudad Autonoma Buenos Aires, Argentina
CEMIC
Ciudad Autonoma Buenos Aires, Argentina
Instituto DAMIC Fundacion Rusculleda
Córdoba, Argentina
Centro Oncologico Riojano Integral (Cori)
La Rioja, Argentina
Centro Oncologico de Parana
Paraná, Argentina
Hospital Universitario Austral
Pilar, Argentina
Instituto Gamma
Rosario, Argentina
Sanatorio Parque S.A.
Rosario, Argentina
Instituto de Oncología de Rosario
Rosario, Argentina
Centro Medico San Roque S.R.L.
San Miguel de Tucumán, Argentina
Showing 40 of 260 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.